Sumanta Pal: Data from the first cohort of STELLAR-001 focused on patients with clear cell renal cell carcinoma
Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared on LinkedIn:
“Grateful to the Kidney Cancer Association for the opportunity to present data from the first cohort of STELLAR-001 focused on patients with clear cell renal cell carcinoma. In 32 patients with heavily pretreated disease (41% with 3 prior lines of therapy) and an aggressive phenotype (38% and 34% with liver and bone metastases, respectively), objective response rate was 38% and disease control rate was 88%. Responses were seen in cabozantinib-exposed patients, and if we focus on cabozantinib-naive patients with prior TKI, response rate was 63% and 100% of patients had disease control. From my experience treating patients on the study, the toxicity profile also compares favorably to other agents in this setting. As an investigative community, we need to get behind ongoing studies of cabozantinib to learn more about this incredibly promising compound (e.g., STELLAR-002; STELLAR-304).”
For the slides click here.
Source: Sumanta Pal/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023